99m锝-甲氧基异丁基异腈SPECT/CT显像对慢性肾病继发甲状旁腺功能亢进甲状旁腺病灶的诊断效能

Diagnostic efficacy of 99Tcm-sestamibi SPECT/CT for parathyroid lesions in patients with secondary hyperparathyroidism caused by chronic kidney disease

二维码有效期 120s

摘要目的探讨SPECT/CT术前准确定位慢性肾病(CKD)继发性甲状旁腺功能亢进(sHPT)患者甲状旁腺病灶的价值.方法 52例甲状旁腺切除术sHPT患者均于术前2周内接受99m锝-甲氧基异丁基异腈(99Tcm-MIBI)双时相平面显像和延迟相SPECT/CT检查.以病理结果为金标准,计算并比较99Tcm-MIBI平面显像、SPECT、CT和SPECT/CT术前检出甲状旁腺病灶的灵敏度、特异度和准确率.方法经手术病理证实,52例共检出172个甲状旁腺病灶,其中甲状旁腺瘤(PM)13个、腺瘤样增生(AH)26个、甲状旁腺增生(PH)133个.99Tcm-MIBI平面显像、SPECT、CT、SPECT/CT诊断甲状旁腺病灶的灵敏度分别为55.81％(96/172)、70.35％(121/172)、79.65％(137/172)和81.40％(140/172),特异度分别为92.05％(81/88)、90.91％(80/88)、76.14％(67/88)和93.18％ (82/88),准确率分别为68.08％ (177/260)、77.31％(201/260)、78.46％ (204/260)和85.38％ (222/260).SPECT/CT的灵敏度明显高于SPECT(x2=17.053,P＜0.001)及99Tcm-MIBI平面显像(x2=44.000,P＜0.001),特异度明显高于CT(x2=10.316,P=0.001),准确率高于CT(x2=13.136,P＜0.001)、SPECT(x2=14.815,P＜0.001)和99Tcm-MIBI平面显像(x2=39.706,P＜0.001).结论 SPECT/CT术前定位诊断sHPT患者甲状旁腺病灶的价值明显优于单一99Tcm-MIBI平面显像、SPECT或CT.